Bullous skin rash

• (2024): Ortiz-Brugués A+, Ann Oncol 35(10), 915-917

Vitiligo

• (2021): Sollena P+, Breast Cancer Res Treat 185(1), 247-253 (16 cases)

Alopecia / hair loss

• (2023): Minta A+, Support Care Cancer 31(12), 717

Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))

• (2024): Zhang C+, Am J Cardiovasc Drugs Dec, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)

Venous thromboembolism

• (2020): Gervaso L+, J Thromb Haemost 18(1), 162-168 [REVIEW]

Anorexia

Hypertransaminasemia (hepatic transaminitis) / elevated transaminases

• (2020): Kovac A+, Cancer Treat Res Commun Aug, Online ahead of print6% (grade 3–4)

Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)

• (2024): She Y+, Front Pharmacol Apr (e-Collection) (pharmacovigilance / pharmacoepidemiology)

Hemotoxicity

• (2018): Kassem L+, Breast Cancer 25(1), 17 [REVIEW]

Leukocytopenia (leukopenia) / leukocytes (white blood cells) decreased

• (2023): Peng TR+, Thorac Cancer Sep, Online ahead of print45%

Neutropenia (neutrophils decreased)

• (2020): Kovac A+, Cancer Treat Res Commun Aug, Online ahead of print50% (grade 3–4)

Arthralgia

• (2021): Andrikopoulou A+, Cancers (Basel) 13(3), 4656–33% [REVIEW] (with an aromatase inhibitor)

Asthenia / fatigue

• (2023): Peng TR+, Thorac Cancer Sep, Online ahead of print51%

Back pain

• (2021): Andrikopoulou A+, Cancers (Basel) 13(3), 4653–9% [REVIEW] (with an aromatase inhibitor)

Bone pain / joint pain

• (2021): Andrikopoulou A+, Cancers (Basel) 13(3), 4653–9% [REVIEW] (with an aromatase inhibitor)

Myalgia/Myositis/Myopathy/Myotoxicity

• (2021): Andrikopoulou A+, Cancers (Basel) 13(3), 4655–12% [REVIEW] (with an aromatase inhibitor)

Interstitial lung disease / interstitial pneumonitis / interstitial pneumonia (cryptogenic organizing pneumonia) / drug-induced interstitial lung disease

• (2023): Schlam I+, Expert Opin Drug Saf 22(12), 1149-1156 [REVIEW]
• (2021): Raschi E+, Breast Cancer Res Treat 186(1), 219-227 (pharmacovigilance / pharmacoepidemiology)

Pulmonary toxicity

• (2019): Jazieh KA+, Expert Rev Anticancer Ther 19(11), 917-919 [REVIEW]

Adverse effects / adverse reactions

• (2024): Wekking D+, Semin Oncol Jan, Online ahead of print [REVIEW]